Stock surges amid guidance: Social media discussions highlighted Geron Corporation's recent 19% share price jump on heavy volume, closing at $1.60 after positive revenue guidance and cash position updates. Observers noted the move could signal renewed interest if the stock sustains above recent lows.
Trial readout in focus: Participants emphasized the upcoming Phase 3 myelofibrosis interim overall survival analysis expected in the second half of 2026 as a key catalyst. Some described the company's operating breakeven trajectory and cash reserves as supportive factors in ongoing conversations.
Sentiment turns positive: Traders expressed hopes for potential buyout scenarios given the biotech's pipeline progress, though caution remained around earnings volatility. Overall discussion reflected cautious optimism on near-term momentum.
Note: This discussion summary was generated from an AI condensation of post data.
Geron Corporation Insider Trading Activity
Geron Corporation insiders have traded $GERN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $GERN stock by insiders over the last 6 months:
- MICHELLE ROBERTSON (EVP, CHIEF FINANCIAL OFFICER) sold 9,855 shares for an estimated $19,118
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive GERN Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
Geron Corporation Hedge Fund Activity
We have seen 116 institutional investors add shares of Geron Corporation stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 20,457,134 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,481,129
- SOLEUS CAPITAL MANAGEMENT, L.P. added 18,218,659 shares (+78.2%) to their portfolio in Q1 2026, for an estimated $27,145,801
- CITADEL ADVISORS LLC added 11,650,783 shares (+117.4%) to their portfolio in Q1 2026, for an estimated $17,359,666
- ABERDEEN GROUP PLC removed 9,527,083 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,195,353
- VESTAL POINT CAPITAL, LP removed 8,780,000 shares (-77.6%) from their portfolio in Q1 2026, for an estimated $13,082,200
- WOODLINE PARTNERS LP removed 7,504,094 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,181,100
- CLEARBRIDGE INVESTMENTS, LLC added 5,377,367 shares (+37.8%) to their portfolio in Q1 2026, for an estimated $8,012,276
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Geron Corporation Stock (GERN) Opinions on Recent Price Surge and Trial Updates
Stock surges amid guidance: Social media discussions highlighted Geron Corporation's recent 19% share price jump on heavy volume, closing at $1.60 after positive revenue guidance and cash position updates. Observers noted the move could signal renewed interest if the stock sustains above recent lows.
Trial readout in focus: Participants emphasized the upcoming Phase 3 myelofibrosis interim overall survival analysis expected in the second half of 2026 as a key catalyst. Some described the company's operating breakeven trajectory and cash reserves as supportive factors in ongoing conversations.
Sentiment turns positive: Traders expressed hopes for potential buyout scenarios given the biotech's pipeline progress, though caution remained around earnings volatility. Overall discussion reflected cautious optimism on near-term momentum.
Note: This discussion summary was generated from an AI condensation of post data.
Geron Corporation Insider Trading Activity
Geron Corporation insiders have traded $GERN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $GERN stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Geron Corporation Hedge Fund Activity
We have seen 116 institutional investors add shares of Geron Corporation stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »